6月30日，恒生指数宣布对恒生港股通创新药指数编制方案进行修订，明确剔除五家CXO（医药合同外包服务）企业，包括药明生物（02269）、药明康德（02359）、金斯瑞（01548）、药明合联（02268）和晶泰控股（02228）。被剔除的CXO公司原先合计权重约20%，其年初以来涨幅均不及指数整体表现。数据显示，2025年初至今，恒生港股通创新药指数涨幅70.8%，而药明生物涨幅仅有49.2%，跑...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.